Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of AK104 (Cadonilimab) in Healthy Chinese Males
NCT05559554Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of cadonilimab in solid tumor (2 arms), sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Area under the plasma concentration-time curve (AUC0-infinity). Started Oct 2022; status: completed.
02
Drugs
cadonilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05559554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559554.